Health · Drug development · published 2026-08-21 · via Endpoints News

Genentech commits $750M to Oregon facility; Bavarian Nordic pushes back Lyme vaccine study

Genentech, a Roche subsidiary, is investing $750 million in a new manufacturing plant for drug delivery devices at its Hillsboro, Oregon site, with operations expected to begin later. Separately, Bavarian Nordic has announced a delay in its Lyme disease trial. The reasons for the delay were not detailed in the brief.

Read the full article at Endpoints News →

Related stories

Roche to invest $750M in Oregon manufacturing expansion · Drug development

Capricor's Duchenne therapy faces delayed FDA decision due to additional data review · Drug development

Celcuity's cancer drug launch delayed pending FDA inspection of second manufacturing site · Drug development

Abcuro secures $66 million to advance Phase 3 trial in milder form of muscle disease · Drug development

This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “Genentech invests $750M in new factory; Bavarian Nordic delays Lyme trial.” Browse more stories.